ClinicalTrials.gg
RecruitingNCT07030283Updated Nov 3, 2026

Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis

A Phase 1 interventional study of Paclitaxel and NALIRIFOX in Pancreatic Ductal Adenocarcinoma (PDAC), sponsored by University of Colorado, Denver. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by University of Colorado, Denver · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.
Updated Nov 3, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 19 studies testing paclitaxel in Peritoneal Neoplasms — 2 open to participants now, 6 under way, 1 of them phase 3. Paclitaxel · Peritoneal Neoplasms.

Planned enrollment
18th of 19
10 · median 35
Started
2025
the only one that year
Phase 1
9 of 19
2 open now
Registered
19th of 19
by date

Among the 19 studies testing paclitaxel in Peritoneal Neoplasms, this one is the 18th largest by planned enrollment, is the only one that started in 2025, is one of 9 in phase 1, and was the 19th registered.

Peritoneal Neoplasms

249 studies on the registry are indexed under Peritoneal Neoplasms; 54 are open to participants now.

Browse Peritoneal Neoplasms studies →

Open to participants now

2 of the 19 studies testing paclitaxel in Peritoneal Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About paclitaxel

Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 48 Peritoneal Neoplasms studies recruiting now, 34 (71%) set no upper age limit and 8 (17%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing paclitaxel in Peritoneal Neoplasms, or all of them as a file.
02

Study summary

This goal of this clinical trial is to learn whether the drug combination of intraperitoneal paclitaxel (chemotherapy given directly into the abdominal cavity) and intravenous NALIRIFOX (chemotherapy given into a vein, including fluorouracil, leucovorin, oxaliplatin, and liposomal irinotecan) is safe and works in adults with pancreatic cancer that has spread to the peritoneum.

The main questions it aims to answer are:

  • Are people with pancreatic cancer able to tolerate the combination drug regimen?
  • How well does the combination drug regimen work to treat pancreatic cancer?

Participants will:

  • Obtain a port that goes into the abdomen to deliver intraperitoneal paclitaxel (called an intraperitoneal catheter)
  • Receive treatment with intravenous NALIRIFOX once every 2 weeks and intraperitoneal paclitaxel on days 1 and 8 of each 14-day cycle
  • Visit the clinic with each treatment for checkups and laboratory testing
  • Have imaging scans and blood lab testing to determine response to treatment
  • Have abdominal fluid lab testing that may help determine if the cancer is responding to treatment
  • Fill out questionnaires to see how the treatment affects how participants feel and function
  • Continue follow up after treatment ends to track survival

Some participants may be able to have surgery later if the cancer responds well. This is called conversion surgery. To be eligible for surgery, the cancer must have shrunk or stayed the same, peritoneal fluid (from the abdomen) must no longer show cancer cells, and a tumor marker called CA 19-9 must decrease or return to normal. The decision to do surgery will depend on the treating surgeon.

By testing this new treatment strategy, researchers hope to find a safer and more effective way to treat people with pancreatic cancer that has spread to the abdomen. If successful, this approach may lead to longer survival, better quality of life, and more people becoming eligible for surgery.

03

Conditions studied

  • Pancreatic Ductal Adenocarcinoma (PDAC)

Keywords

  • Peritoneal Carcinomatosis
  • pancreatic adenocarcinoma
  • pancreatic ductal adenocarcinoma
  • PDAC
  • metastatic
  • NALIRIFOX
  • intraperitoneal chemotherapy
  • intraperitoneal paclitaxel
  • circulating tumor DNA (ctDNA)
  • peritoneal cell-free DNA
04

Who can participate

The criteria were revised on the registry on Nov 3, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision to sign and date the consent form.
  2. Stated willingness to comply with all study procedures and be available for the duration of the study.
  3. Be age 18 years or older.
  4. or cytologically confirmed pancreatic adenocarcinoma with histologically or cytologically proven seeding in the peritoneal cavity without to other organs.
  5. Primary tumor that is resectable, borderline resectable, or locally advanced per NCCN classification.
  6. PCI score ≤ 8.
  7. performance status of 0 or 1
  8. Prior treatment for 0-64 months with FOLFIRINOX, modified FOLFIRINOX, or NALIRIFOX and able to receive additional platinum-based treatment per investigator opinion
  9. Adequate biological parameters as evidenced by all of the following blood counts:

    • (ANC) >/= 1,500 per cubic millimeter without the use of hematopoietic growth factors within 14 days prior to screening
    • count >/= 75,000 per cubic millimeter
    • > 9 g/dL
  10. Adequate hepatic function as evidenced by:

    • Serum total ≤ 1.5x (biliary drainage is allowed for biliary obstruction), and
    • and ALT ≤ 3 x ULN
  11. Adequate renal function as evidenced by serum creatinine \<1.5 x ULN

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment of pancreatic cancer in the setting with surgery or therapy (Note: biliary drainage, diagnostic laparoscopy/laparotomy, and duodenal stenting is allowed).
  2. Evident distant metastatic disease outside of the peritoneal cavity.
  3. Extensive metastatic disease in peritoneal cavity (PCI>8).
  4. Known disease progression with any prior chemotherapy.
  5. Known to paclitaxel or other liposomal products.
  6. Current use of strong CYP2C8 inhibitors or inducers, or presence of any other for paclitaxel.
  7. Known UGT1A1 deficiency or DPD deficiency.
  8. Neuropathy Grade 2 or higher
  9. Known active COVID infection with symptoms.
  10. Has ever received or is currently receiving radiation for pancreatic cancer treatment.
  11. Receipt of live, attenuated vaccine within 30 days prior the first dose of Intraperitoneal paclitaxel. (Note: enrolled patients should not receive during the study and up to 30 days after the last dose of intraperitoneal paclitaxel).
  12. Known positive test results for human immunodeficiency () or patients with chronic or active or C. Patients who have a history of hepatitis B or C who have undetectable HBV DNA or after anti-viral therapy may be enrolled.
  13. Active infection during screening visits or on the day of treatment, which in the investigator's opinion might compromise the patient's participation in the trial or affect the study outcome.
  14. Any other medical or social condition deemed by the Investigator to be likely to interfere with a patient's ability to sign , cooperate and participate in the study, or interfere with the interpretation of the results.
  15. Pregnant or breast feeding; females of must test negative for pregnancy within 7 days prior to C1D1. Both male and female patients of must agree to use a highly effective method of during the study and for 9 months following the last dose of both IP PTX and IV NALIRIFOX.
  16. Histologies other than adenocarcinoma, such as neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma.
  17. Patients who, in the opinion of the investigator, have symptoms or signs suggestive of clinically unacceptable deterioration of the primary disease at the time of screening.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Intraperitoneal Paclitaxel with Systemic NALIRIFOX

    Intraperitoneal paclitaxel will be administered on days 1 and 8 via the intraperitoneal port, and systemic NALIRIFOX (Fluorouracil Continuous Infusion/Leucovorin/Liposomal Irinotecan/Oxaliplatin) will be administered on day 1 of each 14-day cycle. The maximum treatment duration is 12 cycles.

    Drug: Paclitaxel · Drug: NALIRIFOX

Interventions

  • Paclitaxel is a chemotherapy medication that is FDA-approved to treat a number of cancer types. In this study, paclitaxel will be administered via the intraperitoneal port. Intraperitoneal paclitaxel is not FDA approved for pancreatic cancer.

    Also known as: Taxol

  • DrugNALIRIFOX

    NALIRIFOX is a systemic chemotherapy treatment for metastatic pancreatic cancer that was approved by the FDA in February 2024. It's a combination of drugs that are already approved to treat pancreatic cancer: Liposomal irinotecan (Nal-IRI or Onivyde®), 5 fluorouracil (5-FU)/leucovorin, and Oxaliplatin.

06

What researchers measure

Primary outcomes

  1. Adverse event rate

    Time frame: From enrollment through 30 days after last dose of treatment administered (approximately 7 months)

Secondary outcomes

  1. 1-year survival rate

    Time frame: From enrollment through 12 months after the last dose of treatment (approximately 18 months)

  2. Overall survival

    Time frame: From enrollment through 24 months after the last dose of treatment (approximately 30 months)

  3. Progression-free survival

    Time frame: From enrollment through end of treatment (approximately 6 months)

  4. Objective response rate

    Time frame: From enrollment through end of treatment (approximately 6 months)

  5. Change in peritoneal carcinomatosis index

    The peritoneal carcinomatosis index is a score used to assess the amount of cancer in the peritoneal cavity. The score ranges from 0 to 39, with a higher score indicating a greater extent of cancer.

    Time frame: From enrollment to 6 months after end of treatment (approximately 12 months)

Other outcomes

  1. Changes in serum circulating tumor DNA

    Time frame: From enrollment to end of treatment (approximately 6 months)

  2. Conversion surgery rate

    Time frame: From enrollment to end of treatment (approximately 6 months)

  3. Change in quality of life assessed by EORTC QLQ-C30 questionnaire

    The EORTC QLQ-C30 is a validated questionnaire. Scores range from 0 (minimum) to 100 (maximum). Higher scores indicate worse symptoms on symptom scales and better functioning on functional scales.

    Time frame: From enrollment to 6 months after end of treatment (approximately 12 months)

  4. Change in quality of life assessed by EORTC QLQ-PAN26 questionnaire

    The EORTC QLQ-PAN26 is a validated questionnaire. Scores range from 0 (minimum) to 100 (maximum). Higher scores indicate worse symptoms on symptom scales and better functioning on functional scales.

    Time frame: From enrollment to 6 months after end of treatment (approximately 12 months)

  5. Changes in peritoneal cell-free DNA

    Time frame: From enrollment to end of treatment (approximately 6 months)

  6. Changes in tumor markers (CEA and CA 19-9)

    Time frame: From enrollment to end of treatment (approximately 6 months)

  7. Changes in peritoneal cytology

    Time frame: From enrollment to end of treatment (approximately 6 months)

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jul 2028, 30 months after the start.

Of 27 phase 1 interventional studies under Peritoneal Neoplasms, half reached primary completion within 70 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 105. This study's planned 30 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2025
First posted
Jun 22, 2025
StartActual
Dec 31, 2025
Primary completionEst.
Jul 1, 2028
CompletionEst.
Jul 1, 2030
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedPrior treatment for 0-464 months with FOLFIRINOX, modified FOLFIRINOX, or NALIRIFOX and able to receive additional platinum-based treatment per investigator opinion
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Eligibility 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedPrior treatment for 0-464 months with FOLFIRINOX, modified FOLFIRINOX, or NALIRIFOX and able to receive additional platinum-based treatment per investigator opinion

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07030283
Responsible party
Sponsor
First posted
Jun 22, 2025
Start date
Dec 31, 2025
Primary completion
Jul 1, 2028 (estimated)
Completion
Jul 1, 2030 (estimated)
Last update
Nov 3, 2026

Study contacts

Puja Gupta Poddar
Contact
puja.guptapoddar@cuanschutz.edu
720-278-0236
Alexis Leal, MD
principal investigator · University of Colorado, Denver

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paclitaxel

Start the discussion